Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $12.4 million.

  • Agios Pharmaceuticals' Share-based Compensation rose 1105.43% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.3 million, marking a year-over-year increase of 780.85%. This contributed to the annual value of $42.8 million for FY2024, which is 428.67% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Share-based Compensation stood at $12.4 million for Q3 2025, which was up 1105.43% from $14.7 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Share-based Compensation peaked at $15.5 million during Q1 2022, and registered a low of $9.1 million during Q3 2023.
  • For the 5-year period, Agios Pharmaceuticals' Share-based Compensation averaged around $12.0 million, with its median value being $11.6 million (2024).
  • In the last 5 years, Agios Pharmaceuticals' Share-based Compensation plummeted by 3462.93% in 2023 and then surged by 2703.85% in 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Share-based Compensation (Quarter) stood at $11.6 million in 2021, then decreased by 1.34% to $11.5 million in 2022, then rose by 20.49% to $13.8 million in 2023, then decreased by 21.07% to $10.9 million in 2024, then grew by 13.52% to $12.4 million in 2025.
  • Its Share-based Compensation stands at $12.4 million for Q3 2025, versus $14.7 million for Q2 2025 and $11.4 million for Q1 2025.